ABSTRACT A chymostatin-sensitive step in the release of plasminogen activator from transformed fibroblasts has been described recently. By using synthetic peptidyl substrates, we have detected and characterized a ch.ymostatin-sensitive peptidase activity in chicken embryo fibroblasts transformed by Rous sarcoma. virus. The activity represents -a neutral endopeptidase that exhibits phenylalanine specificity and is inhibited by diisopropyl fluorophosphate. A detailed inhibitor profile of the enzyme activity shows that it is distinct from other chymotrypsin-like phenylalanine-preferring peptidases. The endopeptidase activity in transformed fibroblasts is increased over that of parallel cultures of normal fibroblasts. The mechanism of enzyme inhibition by chymostatin is indicated by these studies,.and-the possible role of the enzyme in modulating plasminogen activator secretion is discussed.
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The mechanism whereby specific polypeptides are processed and secreted from cells is well established (1) (2) (3) . The secretory events in this pathway have been defined for a number ofispecific proteins. However, the mode of release of some proteins into the extracellular milieu is not entirely consistent with the features ofthis pathway. The properties ofone such protein, the serine protease plasminogen activator (PA) that is released in enhanced amounts from a variety of activated and transformed cells (4) , indicate that it may not be released via the classical secretory pathway.. The cellular form of PA, in contrast to the soluble released form of the enzyme,-has been shown to be firmly associated with smooth plasma membrane-like elements of the cell (5) . The cell-associated form of PA does not appear to be located within membrane-enclosed vesicles because treatments that readily release vesicle-enclosed enzymes fail to release or solubilize PA (5) . In addition, treatment of Rous sarcoma virus (RSV)-transformed chicken embryo fibroblasts (RSVCEF) with colchicine at concentrations that inhibit the secretion ofother proteins and the -movement ofsecretion granules (6-9) does not inhibit the release of PA (10) . Finally, inhibition ofprotein synthesis for short periods oftime, which has no effect on the secretion of established proteins (11) , rapidly inhibits the release of PA from RSVCEF (10) . Thus, PA appears to exist as a firmly bound membrane-associated enzyme that is actively released into the extracellular medium as a soluble enzyme by an as yet undefined mechanism. It has-been suggested that PA, similar to some tumor-specific proteins, is "shed" from the surface of the malignant cell (12), but conclusive evidence for a PA-shedding phenomenon is still lacking; We have determined that in cultures of RSVCEF the appearance of PA in the extracellular medium is inhibited by the protease inhibitor chymostatin (13) . This inhibition of PA release is accompanied by concomitant accumulation of the cell-associated form of PA.
The effect is specific, is dose and time dependent, and-appears to involve the aldehyde moiety of the chymostatin molecule (13) . By using specific fluorescent substrates, we have found a chymostatin-sensitive.enzyme associated with a membrane. fraction isolated from RSVCEF.
MATERIALS AND METHODS
Cell Culture. Cultures of chicken embryo fibroblasts were prepared, maintained, and infected with RSV as described (5) .
Fluorescence Spectroscopy. The release of 7-amino-4-methylcoumarin (AMC) from the fluorescent substrates Phe-AMC, succinyl (Suc)-Ala-Ala-Phe-AMC, Suc-Ala-Ala-Pro-Ala-AMC, and benzyloxycarbonyl (Cbz)-Gly-Gly-Arg-AMC was measured in a spectrofluorimeter at an excitation wave length of380 nm and an emission wave length of 460 nm (14) . The standard system used to measure hydrolysis of the various substrates consisted of0.5 ml ofa 0. 4 (13) . A chymostatin-sensitive enzymatic activity has been detected in the total membrane fraction isolated from RSVCEF by using the fluorogenic peptide substrate Suc-Ala-Ala-Phe-AMC. Proteases or peptidases that have phenylalanine specificity will cleave on the COOH-terminal side of phenylalanine to release the fluorescent group AMC. The presence of the NH2-terminal succinyl blocking group precludes the activity of amino peptidase-initiated sequential hydrolysis of the substrate. As shown in Fig. 1 A and B, a membrane preparation isolated from RSVCEF exhibits an activity capable of hydrolyzing this substrate that is both time and concentration de- Detection of a chymostatin-sensitive peptidase activity in a RSVCEF membrane fraction. A 0.5-ml assay mixture containing 0.4 mM Suc-Ala-Ala-Phe-AMC in 5% Me2SO/0.05 M Hepes, pH 7.4, was used to detect peptidase activity. (A) Thirty-eight micrograms of total membrane fraction was added to the assay mixture and the release of AMC was measured at the indicated times. (B) Various amounts of membrane protein were added to the assay mixture, release of AMC was monitored for 10 min, and the amount of AMC released per minute was calculated. (C) Forty-six micrograms of total membrane fraction was added to the assay mixture in the presence of various concentrations of chymostatin, the rate of AMC release was measured, and the percent inhibition by chymostatin was calculated.
pendent. Chymostatin inhibits the activity in a dose-dependent manner (Fig. 1C) , yielding essentially total inhibition at a concentration of 100 ,ug/ml (0.17 mM). In separate experiments, it was shown that optimal enzyme activity occurred at pH 7.5-8.1, with little or no activity below pH 6 (Table 1) . This activity, however, is insensitive to chymostatin but is strongly inhibited by the protease inhibitor antipain and thus distinct from the AMC-releasing activity detected when Suc-Ala-AlaPhe-AMC is used. The chymostatin-sensitive activity in the membrane preparation, therefore, appears to be a specific endopeptidase that has phenylalanine specificity. Km Fig. 2) can be inhibited by high concentrations of substrate but that, during prolonged incubation, the aldehyde moiety (phenylalaninal) in chymostatin reacts with the enzyme and irreversibly inhibits it. We have shown previously Inhibitor solutions were prepared at various concentrations, and equal volumes were added to the assay mixture to establish the indicated inhibitor concentration (conc.). At the same concentration of membrane protein and the sensitivity used to measure AMC release from these substrates, no activity capable of hydrolyzing Suc-Ala-Ala-Pro-Ala-AMC was detected (data not shown). NT, not tested.
(13) that reduction of the aldehyde in chymostatin eliminates its antiproteolytic activity.
Inhibitor Profile of RSVCEF Endopeptidase. The effects of several protease inhibitors on the endopeptidase-catalyzed hydrolysis of Suc-Ala-Ala-Phe-AMC are summarized in Table 2 . Effectors of thiol and metallo proteases, inhibitors of trypsinlike enzymes, and the microbial inhibitors elastatinal and bestatin had no effect on the endopeptidase activity. Each ofthese compounds also was incubated with the RSVCEF membranes for 30 min prior to the addition of Suc-Ala-Ala-Phe-AMC and still exhibited no inhibitory effect (data not shown). The only treatments that resulted in significant inhibition ofAMC release were chymostatin and iPr2P-F addition. Incubation ofthe membranes with 1 mM iPr2P-F for 90 min inhibits the rate of hydrolysis to 47% ofthe control rate. Incubation ofthe membranes for 60 min with 2 mM iPr2P-F inhibits the activity 75%. Thus, the membrane endopeptidase is inhibited by iPr2P-F but is not highly sensitive to this specific inhibitor of serine proteases, since, under these conditions, chymotrypsin is inhibited 90-100%.
Membrane Endopeptidase Distinct from Other Phenylalanine-Hydrolyzing Proteins. Chymotrypsin and the cellular proteases cathepsin G and chymase are also capable of cleaving the COOH-terminal side of phenylalanine in synthetic substrates and several groups have reported the effects ofsynthetic and naturally occurring inhibitors on the hydrolytic capacity of these enzymes (17) (18) (19) (20) (21) (22) (23) (24) (25) . To determine whether the RSVCEF membrane endopeptidase was an enzymatic activity similar or different from cathepsin G, chymase, and chymotrypsin, the effects of several highly specific inhibitors on the membranecatalyzed hydrolysis of Suc-Ala-Ala-Phe-AMC were determined. As shown in Table 3 , the RSVCEF endopeptidase has an inhibitor pattern distinct from that of the other three enzymes. The membrane endopeptidase is most strongly inhibited by chymostatin but considerable inhibition of the activity also is obtained with the tripeptide chloromethylketone, CbzGly-Leu-Phe-CH2Cl. Bz-Phe-al, Tos-PheCH2Cl, and a-i-antichymotrypsin have little or no effect on the membrane endopeptidase. In contrast, chymotrypsin is markedly inhibited by all five compounds; chymase is sensitive to a-l-antichy- motrypsin and Tos-PheCH2Cl; and cathepsin G, although inhibited by chymostatin and Cbz-Gly-Leu-Phe-CH2Cl, is also sensitive to Tos-PheCH2Cl and a-l-antichymotrypsin.
Endopeptidase Activity in Normal Chicken Embryo Fibroblasts and RSVCEF. The endopeptidase activities in cell lysates prepared from parallel cultures of normal chicken embryo fibroblasts and RSVCEF are shown in Table 4 . The level of enzyme in normal chicken embryo fibroblasts is increased approximately 3-fold following transformation by RSV. The activity in both cultures is inhibited 90% by chymostatin at 50 jig/ ml.
DISCUSSION
The inhibition by chymostatin of PA release from cultures of RSVCEF (13) has led to the identification and partial charac- Parallel cultures of normal and transformed fibroblasts were harvested during exponential growth. Cellular homogenates were prepared, and multiple aliquots of the homogenates were assayed for endopeptidase activity and protein content. Results are expressed as pmol of AMC released/pug of protein per hr and represent mean ± SD.
terization ofa chymostatin-sensitive enzyme activity in RSVCEF. This activity appears to be due to a membrane endopeptidase that cleaves on the COOH-terminal side of phenylalanine in synthetic peptide substrates ( Table 1 ). The inhibitor profile indicates that the endopeptidase is not a thiol or metallo enzyme but rather a serine peptidase inhibitable by iPr2P-F ( Table 2 ). The enzyme activity, when compared with those of purified serine proteases, does not exhibit a high sensitivity to iPr2P-F. however, the heterogeneous nature ofthe membrane fraction that contains the endopeptidase may influence its reactivity with iPr2P-F. The membrane-associated form of PA isolated from these cells likewise requires relatively high levels ofiPr2P-F for inhibition compared with the levels required for the purified soluble form of PA (26) .
The RSVCEF endopeptidase appears to be distinct from chymotrypsin and two other phenylalanine-preferring chymotrypsin-like cellular enzymes, cathepsin G and chymase (Table 3) . Although some similarities do exist between the inhibitor profile of the endopeptidase and the profile of these other proteolytic enzymes, distinct discrepancies are apparent. These data suggest that the RSVCEF endopeptidase represents an as yet undescribed enzyme activity; however, it is important to point out that a crude form ofthe endopeptidase was assayed in these studies and compared with highly purified forms of the other enzymes (Table 3) . A truly valid comparison must await purification of the endopeptidase.
A chymostatin-sensitive membrane-associated endopeptidase also has been reported by Zimmerman and co-workers (27, 28) . This activity was detected by deoxycholate-solubilize pancreatic microsomal membranes by using the same synthetic sbstrate, Suc-Ala-Ala-Phe-AMC. The microsomal endopeptidase, however, was reported to cleave the substrate between alanine and phenylalanine and to be inhibited by 1, 10-phen- Inhibition (23, 24) Inhibitors at the indicated concentrations (conc.) were incubated with membrane (10 ug) anthroline (28) . In contrast, the RSVCEF endopeptidase cleaves on the COOH-terminal side of phenylalanine and is insensitive to 1, 10-phenanthroline (Table 2 ) and thus is distinct from the microsomal endopeptidase.
The mechanism of inhibition by chymostatin of the RSVCEF endopeptidase has been suggested by these studies. The data in Table 3 indicate that the effect of chymostatin on the enzyme is not just due to the terminal phenylalaninal residues since the simple phenylalaninal compound, Bz-Phe-al elicits no inhibitory effect. Similarly, the terminal phenylalanine chloromethyl ketone in Cbz-Gly-Leu-Phe-CH2Cl is not solely responsible for enzyme inhibition because the endopeptidase is insensitive to the simple phenylalanine chloromethyl ketone compound, TosPheCH2Cl. The inhibitory effects ofboth chymostatin and CbzGly-Leu-Phe-CH2Cl therefore suggest that the tripeptide structure Gly-Leu-Phe is necessary to position the inhibitor at the active site of the enzyme. Once bound to the active site, either the aldehyde or chloromethyl ketone group can react to inactivate the enzyme. The kinetic data in Fig. 3 are consistent with a competition for active site binding between the Gly-LeuPhe-al moiety of chymostatin and the Ala-Ala-Phe-AMC of the substrate. The time-dependent occurrence of irreversible inhibition is likewise consistent with aldehyde-mediated inhibition of the enzyme following chymostatin binding.
It is tempting to speculate that the RSVCEF endopeptidase activity described herein is involved in the mechanism of PA release. The release of PA from a firmly bound membrane state to a soluble extracellular form does not appear to proceed via the classical secretion pathway. The release of PA from these cells, however, is sensitive to chymostatin and the inhibitory effect of chymostatin on PA release appears to be due specifically to the antiproteolytic activity ofchymostatin (13) . The only detectable chymostatin-sensitive peptidase activity in RSVCEF cultures is the described endopeptidase ( Table 1) . The endopeptidase activity is enhanced after transformation of chicken embryo fibroblasts by RSV (Table 4) , an event that also leads to increased production of PA (4) . A number of other cell cultures have been examined including B16 melanoma and human fibrosarcoma HT-1080. Similar to the RSVCEF cultures, the release of PA from these mammalian cultures is inhibited by chymostatin and the cells also possess a chymostatin-sensitive endopeptidase activity (unpublished data). These observations provide further support for a role of the endopeptidase in PA release. However, there are some unresolved questions that prevent the establishment of a direct link between endopeptidase activity and PA release. First, the concentration of chymostatin that is required to completely inhibit the endopeptidase activity (50-100 ug/ml) is 15-30% of that needed in culture medium to inhibit PA release (300 jig/ml). This may be due to an inability to estimate the effective concentration of chymostatin at the cell surface because chymostatin is relatively insoluble in aqueous culture medium (13) . Also, an inaccessibility of the cellular endopeptidase to exogenous chymostatin may require high concentrations of the compound in the extracellular medium. A second unresolved question is that the natural substrate for the endopeptidase has not been established. Although the cellular form of PA is firmly bound to RSVCEF membranes (5), the molecular mass ofthe released extracellular form of PA is identical (within 1,000 daltons) to that of the cellassociated form (10) . Therefore, if the endopeptidase functions proteolytically to release PA from its membrane association, it would not appear to cleave a large membrane-bound segment of the PA molecule. Instead, the endopeptidase may cleave other membrane proteins that directly or indirectly interact with PA. The cleavage of these proteins could perturb the association of PA with the membrane, resulting in the release of soluble PA into the extracellular medium. However, until such a putative substrate is found, the link between endopeptidase activity and PA release remains circumstantial. Nevertheless, the circumstantial evidence that links the two enzymes-i.e., chymostatin sensitivity-has allowed for the detection of this apparently unique endopeptidase activity in transformed fibroblasts. Its purification, now feasible because of its specific inhibitor profile and reactivity toward defined synthetic substrates, should allow for both the identification of its natural substrate(s) and the elucidation of its role in the subtle, yet influential, protein perturbations that occur in normal and transformed cell membranes.
